Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study

Leukemia Research

Volumn 37, Issue 8, 2013, Pages 862-867

  Okuyama, Namiko ^a   Sperr, Wolfgang R ^b   Kadar, Katalin ^c   Bakker, Sietske ^d   Szombath, Gergely ^c   Handa, Hiroshi ^e   Tamura, Hideto ^a   Kondo, Asaka ^a   Valent, Peter ^b   Várkonyi, Judit ^c   van de Loosdrecht, Arjan ^d   Ogata, Kiyoyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e GUNMA UNIVERSITY   (Japan)

Author keywords

Acute myeloid leukemia; Allogeneic transplantation; Myelodysplastic syndromes; Performance status; Prognosis; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BEST SUPPORTIVE CARE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTE COUNT;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; DRUG THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879786561     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.02.018     Document Type: Article

References (26)

1. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
2. Sekeres M.A. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010, 24:287-294.
3. Neukirchen J., Schoonen W.M., Strupp C., Gattermann N., Aul C., Haas R., et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res 2011, 35:1591-1596.
4. Della Porta M.G., Malcovati L., Strupp C., Ambaglio I., Kuendgen A., Zipperer E., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96:441-449.
5. Gardin C., Chaibi P., de Revel T., Rousselot P., Turlure P., Miclea J.M., et al. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia, Club de Reflexion en Hematologie. Leukemia 1997, 11:16-21.
6. Knipp S., Hildebrand B., Kundgen A., Giagounidis A., Kobbe G., Haas R., et al. Intensive chemotherapy is not recommended for patients aged>60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007, 110:345-352.
7. Rizzieri D.A., O'Brien J.A., Broadwater G., Decastro C.M., Dev P., Diehl L., et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 2009, 115:2922-2929.
8. Morita Y., Kanamaru A., Miyazaki Y., Imanishi D., Yagasaki F., Tanimoto M., et al. Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol 2010, 91:97-103.
9. Bello C., Yu D., Komrokji R.S., Zhu W., Wetzstein G.A., List A.F., et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011, 117:1463-1469.
10. Kadia T.M., Jabbour E., Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 2011, 38:682-692.
11. Oka Y., Tsuboi A., Oji Y., Kawase I., Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008, 20:211-220.
12. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. [erratum appears in Blood 1998, February 1; 91:1100].
13. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
14. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
15. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
16. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
17. Shaffer L.G., Slovak M.L., Campbell L.J. An international system for human cytogenetic nomenclature (2009): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature 2009, Karger, Basel.
18. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
20. Smith M.L., Hills R.K., Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011, 25:39-51.
21. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
22. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
23. Nolte F., Hofmann W.K. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 2010, 6:445-455.
24. Davids M.S., Steensma D.P. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther 2010, 10:309-319.
25. Ishibashi M., Tamura H., Ogata K. Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment. Leuk Res 2011, 35:1449-1452.
26. Ogata K., Kakumoto K., Matsuda A., Tohyama K., Tamura H., Ueda Y., et al. Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res 2012, 36:1229-1236.